Annual report
4564.TEDINET S100OBQJ
Period2021-04-01 → 2022-03-31
Filed2022-06-21
StandardJapan GAAP
ConsolidatedYes
Data checks20 of 20 passed
Key figures · 124
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥332m | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Operating income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | −¥1.6bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.6bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥3.0bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥3.0bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥1.6bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.6bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.9bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | −¥1.6bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥2.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥3.4bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥5.1bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.4bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.0bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥705m | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥291m | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.7bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥4.9bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥7.6bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.9bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥6.7bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.8bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥2.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥2.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥3.0bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥468m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥52m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥31m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥74m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥446m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥566m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥151m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.86 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.73 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-19.9 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-19.39 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥9.84 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥16.96 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥25.81 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥30.32 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥47.44 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.8% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.6% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.0% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 67 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 66 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 62 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 63 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 56 | at 2018-03-31d | Cons. | Number of employees |
| Operating income | −¥2.0bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | −¥1.4bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | −¥2.0bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.8bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.7bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥2.4bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.5bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | −¥2.4bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | −¥1.5bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | −¥2.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥3.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥2.6bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.1bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥2.9bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥4.6bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.5bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥418m | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥245m | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.7bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.6bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.3bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.1bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.4bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-12.94 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.77 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.13 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-23.05 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-17.85 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥8.38 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥14.53 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥23.31 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥25.75 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥45.89 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 76.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.2% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.0% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 192,643,700 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 176,332,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 176,332,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 151,557,400 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 147,032,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 36 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 35 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 32 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 37 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 40 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥952,000 |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥6m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥9m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥9m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥683m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥368m |
| Cancer Precision Medical Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥468m |
| Cancer Precision Medical Businessreportable segment | employees | at 2022-03-31 | 31 pure |
| Cancer Precision Medical Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| Cancer Precision Medical Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.1bn |
| Cancer Precision Medical Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥8m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2022-03-31 | ¥1.0bn |
| Cancer Precision Medical Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥49m |
| Research And Development Of Pharmaceutical Productsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2m |
| Research And Development Of Pharmaceutical Productsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥11m |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2022-03-31 | 36 pure |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥7m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥7m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥166,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2022-03-31 | ¥2.3bn |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥1.6bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥469m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥11m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥9m |
| —segment total | segment assets | at 2022-03-31 | ¥3.4bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥29m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥15m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥50m |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥50m |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥6m |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥214m |
| Cancer Precision Medical Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥11m |
| Cancer Precision Medical Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥272m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥221m |
| Cancer Precision Medical Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥50m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2021-03-31 | ¥254m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | −¥293m |
| Research And Development Of Pharmaceutical Productsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥2m |
| Research And Development Of Pharmaceutical Productsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥34m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥111m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥111m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥55,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2021-03-31 | ¥3.1bn |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | −¥1.1bn |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥13m |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥34m |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥383m |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥332m |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥50m |
| —segment total | segment assets | at 2021-03-31 | ¥3.4bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | −¥1.4bn |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2022-03-31 | 36 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,183
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | － | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | － | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | － | |
| Number of male directors and other officers | FilingDateInstant | 7 | |
| Number of female directors and other officers | FilingDateInstant | 2 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.222 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000JAEHYUNPARKMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000KatoHatsuoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000ShimadaJunichiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000KatagiriToyomasaMember | 25000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000MikiYoshioMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000KomineYuichiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000YamaneYukaMember | 50000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000TakagiMiyakoMember | 31000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000TajimaTeruhisaMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 106000 | |
| Audit fees reporting company | Prior1YearDuration | 19500000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
| Audit fees reporting company | CurrentYearDuration | 19500000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | － | JPY |
| Audit fees consolidated subsidiaries | Prior1YearDuration | － | JPY |
| Non audit fees consolidated subsidiaries | Prior1YearDuration | － | JPY |
| Audit fees consolidated subsidiaries | CurrentYearDuration | － | JPY |
| Non audit fees consolidated subsidiaries | CurrentYearDuration | － | JPY |
| Audit fees total | Prior1YearDuration | 19500000 | JPY |
| Non audit fees total | Prior1YearDuration | － | JPY |
| Audit fees total | CurrentYearDuration | 19500000 | JPY |
| Non audit fees total | CurrentYearDuration | － | JPY |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 47477000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 38750000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 8727000 | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 3 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 7528000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 7250000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 278000 | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 2 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 20837000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 12109000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 8727000 | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 5 | |
| Cash and deposits | Prior1YearInstant | 2899092000 | JPY |
| Cash and deposits | CurrentYearInstant | 1836906000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 20 of 20 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |